ClinicalTrials.gg
RecruitingNCT07862829Updated Oct 7, 2026

Integration of the Oura Ring and Maven Clinic Among Women Who Are Trying to Conceive

An observational study in Trying to Conceive, sponsored by Ouraring Inc.. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Ouraring Inc. · Observational

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Oct 7, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50,000
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

This study aims to characterize Oura Ring users who are trying to conceive. It also evaluates the feasibility and clinical outcomes of integrating Oura data with Maven's clinical support platform.

02

Conditions studied

  • Trying to Conceive

Keywords

  • Fertility
  • Pregnancy
  • Conception
03

In context

Lead sponsor

Ouraring Inc. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Individuals residing in the United States who use Oura Ring and self identify as trying to conceive.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

18-45 years old Female sex at birth Currently trying to conceive Able to provide consent electronically Have an Oura Ring (Gen 3 or newer) with an active account Can communicate and provide consent using written and spoken English Lives in the US

Exclusion criteria

Exclusion Criteria:

Currently using hormonal Currently pregnant

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Primary Outcome Measure

    To describe users who are trying to conceive with the use of Maven and/or the Oura Ring, including their health characteristics, knowledge on trying to conceive, stage along their conception journey, reproductive history and behaviors, and engagement with health resources.

    Time frame: Up to 12 months

07

Study locations

1 of 1 sites recruiting
  • Maven Clinic
    New York, New York 10013, United States
    Recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Jul 2029, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2026
First posted
Oct 7, 2026
StartActual
Jul 29, 2026
Primary completionEst.
Jul 29, 2029
CompletionEst.
Jul 29, 2029
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07862829
Lead sponsor
Ouraring Inc.
Collaborators
Maven Clinic
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Jul 29, 2026
Primary completion
Jul 29, 2029 (estimated)
Completion
Jul 29, 2029 (estimated)
Last update
Oct 7, 2026

Study contacts

Hannah Jahnke, PhD
Contact
research@mavenclinic.com
877-628-3483
Natalie Henrich, PhD, MPH
principal investigator · Maven Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion